Skip to content
-
Xspray Pharma Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)
Feb 23, 2023
STOCKHOLM – February 23, 2023 – Xspray Pharma AB, (NASDAQ Stockholm: XSPRAY) has signed an agreement... read more
-
Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Analysis for Diabetic Gastroparesis Patients Treated with GIMOTI® Versus Oral Metoclopramide at the Digestive Disease Week Plenary Session
Feb 23, 2023
SOLANA BEACH, Calif., and CHICAGO, IL., February 21, 2023 – Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty... read more
-
Spotlight: Corporate Member of the Month, February 2023
Feb 20, 2023
NASP is pleased to shine a bright light this week on Perigon Pharmacy 360, the third... read more
-
Spotlight: Corporate Member of the Month, February 2023
Feb 13, 2023
NASP is pleased to shine a bright light this week on Genentech, the second corporate member... read more
-
NASP hosts CLE Webinar for Healthcare Attorneys
Feb 09, 2023
NASP is pleased to announce that it will host a one-hour webinar on legal ethics for... read more
-
NASP Urges Participation in the 2023 SPCB Job Analysis Survey
Feb 07, 2023
The National Association of Specialty Pharmacy (NASP) is urging its members and all industry stakeholders to... read more
-
Listen to the NASP Post Show Podcasts
Feb 06, 2023
Whether you attended the NASP 2022 Annual Meeting & Expo or are just curious about our... read more
-
Spotlight: Corporate Member of the Month, February 2023
Feb 06, 2023
NASP is pleased to shine a bright light this week on Shipment Trackers, the first corporate... read more
-
Spotlight: Corporate Members of the Month, February 2023
Feb 01, 2023
NASP is pleased to announce the February Spotlight: NASP Corporate Members of the Month! This month, we’ll... read more
-
Spotlight: Corporate Member of the Month, January 2023
Jan 30, 2023
NASP is pleased to shine a bright light this week on Optum Frontier Therapies, the fourth... read more